From GlobeNewswire: 2025-03-27 08:05:00

AIM ImmunoTech Inc. continues clinical development programs for Ampligen in areas with critical unmet needs, focusing on pancreatic cancer. Expected milestones over 18 months include trials partially funded by AstraZeneca and Merck. Conference call on April 1st at 8:30 AM ET to discuss financial results and business update.

Recent highlights include plans for an influenza vaccine study, new Board members, and progress in clinical trials for pancreatic cancer. AIM expands patent portfolio for Ampligen. Financially, AIM reports $4.0 million in cash as of December 31, 2024, with reduced expenses in research and development.

Expected upcoming milestones include trials for metastatic pancreatic cancer, refractory melanoma, triple negative breast cancer, and advanced ovarian cancer. Funding for trials comes from collaborations with AstraZeneca, Merck, and the National Cancer Institute. Key milestones expected in 2025 and 2026.

Interested participants can access the conference call and webcast discussing AIM’s operational and financial results on April 1st at 8:30 AM ET. AIM ImmunoTech Inc. is a company focused on developing therapeutics for cancers, immune disorders, and viral diseases. Lead product, Ampligen, is in clinical trials for various conditions.



Read more at GlobeNewswire:: AIM ImmunoTech Reports Fourth Quarter and Full Year 2024